Compare $CLDX vs $NRIX | Chartloom

Compare

$CLDX vs $NRIX

Celldex Therapeutics Inc · Nurix Therapeutics Inc

CLDX

Celldex Therapeutics Inc

NRIX

Nurix Therapeutics Inc

Compare $CLDX vs $NRIX

Comparing Celldex Therapeutics Inc and Nurix Therapeutics Inc

CLDXCelldex Therapeutics Inc

NRIXNurix Therapeutics Inc

CLDXCelldex Therapeutics Inc

Market cap

$2.35B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1,016.81x

Rev growth (TTM)

-97.3%

YTD performance

10.7%

52W performance

9.7%

FCF yield

-10.3%

NRIXNurix Therapeutics Inc

Market cap

$2.32B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

24.84x

Rev growth (TTM)

-58.4%

YTD performance

23.8%

52W performance

123.9%

FCF yield

-13.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLDX

NRIX

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

NRIX

Nurix Therapeutics Inc

Market Cap

CLDX$2.35B

NRIX$2.32B

Enterprise Value

CLDX$2.30B

NRIX$2.25B

Price

CLDX$29.89

NRIX$22.35

P/E Ratio

CLDXN/A

NRIXN/A

P/S Ratio

CLDX14,848.52x

NRIX63.09x

EV/Sales

CLDX14,548.18x

NRIX61.25x

EV/EBITDA

CLDX0.00x

NRIX0.00x

P/B Ratio

CLDX3.48x

NRIX5.93x

P/FCF Ratio

CLDXN/A

NRIXN/A

EV/FCF

CLDX-9.49x

NRIX-7.39x

PEG Ratio

CLDXN/A

NRIXN/A

Forward P/E (NTM)

CLDXN/A

NRIXN/A

Forward P/S (NTM)

CLDX1,016.81x

NRIX24.84x

Revenue (TTM)

CLDX$158K

NRIX$37M

Revenue Growth (YoY)

CLDX-97.3%

NRIX-58.4%

Forward Rev Growth

CLDX637.2%

NRIX66.6%

Gross Margin (TTM)

CLDX17.6%

NRIX0.0%

Operating Margin (TTM)

CLDX0.0%

NRIX0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

NRIX-959.0%

Net Margin (TTM)

CLDX-190220.9%

NRIX-928.4%

FCF Margin (TTM)

CLDX-153231.0%

NRIX-828.3%

Net Income (TTM)

CLDX$-301M

NRIX$-341M

FCF (TTM)

CLDX$-242M

NRIX$-305M

EPS (TTM)

CLDX-$3.86

NRIX-$3.07

ROE (TTM)

CLDX-5235.0%

NRIX-7609.0%

ROA (TTM)

CLDX-4761.0%

NRIX-5732.0%

ROIC (TTM)

CLDX-5235.0%

NRIX-7609.0%

Cash

CLDX$47M

NRIX$68M

Debt

CLDX$0

NRIX$0

Net Cash/Debt

CLDX$47M

NRIX$68M

Current Ratio (TTM)

CLDX11.82x

NRIX6.34x

Quick Ratio (TTM)

CLDX11.71x

NRIX6.16x

Debt/Equity (TTM)

CLDX0.00x

NRIX0.00x

Debt/Assets (TTM)

CLDX0.0%

NRIX0.0%

Interest Coverage (TTM)

CLDXN/A

NRIXN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

NRIX0.00x

Beta

CLDX0.99

NRIX1.78

52W Performance

CLDX9.7%

NRIX123.9%

YTD Performance

CLDX10.7%

NRIX23.8%

% from 52W High

CLDX-33.8%

NRIX-20.8%

% from 52W Low

CLDX35.2%

NRIX148.3%

Asset Turnover (TTM)

CLDX0.00x

NRIX0.06x

FCF Yield (TTM)

CLDX-10.3%

NRIX-13.1%

Earnings Yield (TTM)

CLDX-12.8%

NRIX-14.7%

Dividend Yield (TTM)

CLDXN/A

NRIXN/A

Rule of 40

CLDX-153,328.3

NRIX-886.7

EV/GP/RG

CLDX42.93

NRIXN/A

Ticker research

View CLDX research View NRIX research

Metric	CLDX Celldex Therapeutics Inc	NRIX Nurix Therapeutics Inc
Market & Valuation
Market Cap	$2.35B	$2.32B
Enterprise Value	$2.30B	$2.25B
Price	$29.89	$22.35
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	63.09x
EV/Sales	14,548.18x	61.25x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	5.93x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-7.39x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1,016.81x	24.84x
Revenue & Growth
Revenue (TTM)	$158K	$37M
Revenue Growth (YoY)	-97.3%	-58.4%
Forward Rev Growth	637.2%	66.6%
Profitability
Gross Margin (TTM)	17.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	-959.0%
Net Margin (TTM)	-190220.9%	-928.4%
FCF Margin (TTM)	-153231.0%	-828.3%
Net Income (TTM)	$-301M	$-341M
FCF (TTM)	$-242M	$-305M
EPS (TTM)	-$3.86	-$3.07
ROE (TTM)	-5235.0%	-7609.0%
ROA (TTM)	-4761.0%	-5732.0%
ROIC (TTM)	-5235.0%	-7609.0%
Financial Health
Cash	$47M	$68M
Debt	$0	$0
Net Cash/Debt	$47M	$68M
Current Ratio (TTM)	11.82x	6.34x
Quick Ratio (TTM)	11.71x	6.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.78
52W Performance	9.7%	123.9%
YTD Performance	10.7%	23.8%
% from 52W High	-33.8%	-20.8%
% from 52W Low	35.2%	148.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-10.3%	-13.1%
Earnings Yield (TTM)	-12.8%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	-886.7
EV/GP/RG	42.93	N/A
Ticker research	View CLDX research	View NRIX research

Valuation

P/S Ratio

NRIX

63.09x

CLDX

14,848.52x

EV/FCF

CLDX

-9.49x

NRIX

-7.39x

Growth & revenue

Revenue Growth TTM

NRIX

-58.4%

CLDX

-97.3%

Forward Revenue Growth

CLDX

637.2%

NRIX

66.6%

Profitability & performance

Gross Margin

CLDX

17.6%

NRIX

0.0%

ROE

CLDX

-5235.0%

NRIX

-7609.0%

FCF Yield %

CLDX

-10.3%

NRIX

-13.1%

52-Week Performance

NRIX

123.9%

CLDX

9.7%

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

NRIX

Nurix Therapeutics Inc

Market Cap

CLDX$2.35B

NRIX$2.32B

Enterprise Value

CLDX$2.30B

NRIX$2.25B

Price

CLDX$29.89

NRIX$22.35

P/E Ratio

CLDXN/A

NRIXN/A

P/S Ratio

CLDX14,848.52x

NRIX63.09x

EV/Sales

CLDX14,548.18x

NRIX61.25x

EV/EBITDA

CLDX0.00x

NRIX0.00x

P/B Ratio

CLDX3.48x

NRIX5.93x

P/FCF Ratio

CLDXN/A

NRIXN/A

EV/FCF

CLDX-9.49x

NRIX-7.39x

PEG Ratio

CLDXN/A

NRIXN/A

Forward P/E (NTM)

CLDXN/A

NRIXN/A

Forward P/S (NTM)

CLDX1,016.81x

NRIX24.84x

Revenue (TTM)

CLDX$158K

NRIX$37M

Revenue Growth (YoY)

CLDX-97.3%

NRIX-58.4%

Forward Rev Growth

CLDX637.2%

NRIX66.6%

Gross Margin (TTM)

CLDX17.6%

NRIX0.0%

Operating Margin (TTM)

CLDX0.0%

NRIX0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

NRIX-959.0%

Net Margin (TTM)

CLDX-190220.9%

NRIX-928.4%

FCF Margin (TTM)

CLDX-153231.0%

NRIX-828.3%

Net Income (TTM)

CLDX$-301M

NRIX$-341M

FCF (TTM)

CLDX$-242M

NRIX$-305M

EPS (TTM)

CLDX-$3.86

NRIX-$3.07

ROE (TTM)

CLDX-5235.0%

NRIX-7609.0%

ROA (TTM)

CLDX-4761.0%

NRIX-5732.0%

ROIC (TTM)

CLDX-5235.0%

NRIX-7609.0%

Cash

CLDX$47M

NRIX$68M

Debt

CLDX$0

NRIX$0

Net Cash/Debt

CLDX$47M

NRIX$68M

Current Ratio (TTM)

CLDX11.82x

NRIX6.34x

Quick Ratio (TTM)

CLDX11.71x

NRIX6.16x

Debt/Equity (TTM)

CLDX0.00x

NRIX0.00x

Debt/Assets (TTM)

CLDX0.0%

NRIX0.0%

Interest Coverage (TTM)

CLDXN/A

NRIXN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

NRIX0.00x

Beta

CLDX0.99

NRIX1.78

52W Performance

CLDX9.7%

NRIX123.9%

YTD Performance

CLDX10.7%

NRIX23.8%

% from 52W High

CLDX-33.8%

NRIX-20.8%

% from 52W Low

CLDX35.2%

NRIX148.3%

Asset Turnover (TTM)

CLDX0.00x

NRIX0.06x

FCF Yield (TTM)

CLDX-10.3%

NRIX-13.1%

Earnings Yield (TTM)

CLDX-12.8%

NRIX-14.7%

Dividend Yield (TTM)

CLDXN/A

NRIXN/A

Rule of 40

CLDX-153,328.3

NRIX-886.7

EV/GP/RG

CLDX42.93

NRIXN/A

Ticker research

View CLDX research View NRIX research

Metric	CLDX Celldex Therapeutics Inc	NRIX Nurix Therapeutics Inc
Market & Valuation
Market Cap	$2.35B	$2.32B
Enterprise Value	$2.30B	$2.25B
Price	$29.89	$22.35
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	63.09x
EV/Sales	14,548.18x	61.25x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	5.93x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-7.39x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1,016.81x	24.84x
Revenue & Growth
Revenue (TTM)	$158K	$37M
Revenue Growth (YoY)	-97.3%	-58.4%
Forward Rev Growth	637.2%	66.6%
Profitability
Gross Margin (TTM)	17.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	-959.0%
Net Margin (TTM)	-190220.9%	-928.4%
FCF Margin (TTM)	-153231.0%	-828.3%
Net Income (TTM)	$-301M	$-341M
FCF (TTM)	$-242M	$-305M
EPS (TTM)	-$3.86	-$3.07
ROE (TTM)	-5235.0%	-7609.0%
ROA (TTM)	-4761.0%	-5732.0%
ROIC (TTM)	-5235.0%	-7609.0%
Financial Health
Cash	$47M	$68M
Debt	$0	$0
Net Cash/Debt	$47M	$68M
Current Ratio (TTM)	11.82x	6.34x
Quick Ratio (TTM)	11.71x	6.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.78
52W Performance	9.7%	123.9%
YTD Performance	10.7%	23.8%
% from 52W High	-33.8%	-20.8%
% from 52W Low	35.2%	148.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-10.3%	-13.1%
Earnings Yield (TTM)	-12.8%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	-886.7
EV/GP/RG	42.93	N/A
Ticker research	View CLDX research	View NRIX research